Search

Your search keyword '"Skene, Allan M."' showing total 23 results
Start Over Author "Skene, Allan M."
23 results on '"Skene, Allan M."'

5. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial

Author

Dormandy, John A., Charbonnel, Bernard, Eckland, David J.A., Erdmann, Erland, Benedetti, Massimo Massi, Moules, Ian K., Skene, Allan M., Tan, Meng H., Lefebvre, Pierre J., Murray, Gordon D., Standl, Eberhard, Wilcox, Robert G., Wilhelmsen, Lars, Betteridge, John, Birkeland, Kare, Golay, Alain, Heine, Robert J., Koranyi, Laszlo, Laakso, Markku, Mokan, Marian, Norkus, Antanas, Pirags, Valdis, Podar, Toomas, Scheen, Andre, Scherbaum, Werner, Schernthaner, Guntram, Schmitz, Ole, Skrha, Jan, Smith, Ulf, and Taton, Jan

Subjects
Type 2 diabetes -- Complications and side effects, Type 2 diabetes -- Care and treatment, Type 2 diabetes -- Physiological aspects, Type 2 diabetes -- Drug therapy, Cardiovascular diseases -- Risk factors, Cardiovascular diseases -- Causes of, Cardiovascular diseases -- Prevention
Published
2005

6. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome

Author

Cannon, Christopher P., McCabe, Carolyn H., Muhlestein, Brent, Cairns, Richard, Braunwald, Eugene, Grayston J. Thomas, Giugliano, Robert P., and Skene, Allan M.

Subjects
Antibiotics -- Health aspects, Coronary heart disease -- Risk factors, Chlamydia -- Care and treatment
Abstract

The antibiotic treatment of Chlamydia pneumoniae found within atherosclerotic plaques, and elevated titers of antibody to this organism linked to a higher risk of coronary events is studied. It is concluded that despite long-term treatment with a bactericidal antibiotic effective against Chlamydia pneumoniae, no reduction in the rate of cardiovascular events was observed.

Published
2005

7. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

Author

Sabatine, Marc S., Gibson, C. Michael, Montalescot, Gilles, Claeys, Marc J., Skene, Allan M., Braunwald, Eugene, McCabe, Carolyn H., Hill, Karen A., Cools, Frank, Theroux, Pierre, and Lopez-Sendon, Jose L.

Subjects
Plavix (Medication) -- Usage, Thrombolytic drugs -- Usage, Heart attack -- Drug therapy
Abstract

A study is conducted enrolling 3491 patients in the age group of 18 to 75 years of age, who presented within 12 hours after the onset of an ST-elevation myocardial infarction and randomly assigned them to receive clopidogrel or placebo. In patients 75 years or younger who have myocardial infraction with ST-segment elevation, the addition of clopidogrel improves the patency rate of the infarct-related artery and reduces ischemic complications.

Published
2005

8. Intensive versus moderate lipid lowering with statins after acute coronary syndromes

Author

Cannon, Christopher P., Braunwald, Eugene, McCabe, Carolyn H., Rader, Daniel J., Pfeffer, Marc A., Skene, Allan M., Rouleau, Jean L., Belder, Rene, Joyal, Steven V., and Hill, Karen A.

Subjects
Cardiovascular diseases -- Risk factors, Cardiovascular diseases -- Drug therapy, Antilipemic agents -- Evaluation, Statins -- Evaluation
Abstract

The risk of Cardiovascular events may be reduced by Lipid-lowering therapy with statins. An intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events for patients who have had an acute coronary syndrome.

Published
2004

12. Reply

Author

Erdmann, Erland, primary, Dormandy, John A., additional, Charbonnel, Bernard, additional, Massi-Benedetti, Massimo, additional, Moules, Ian K., additional, and Skene, Allan M., additional

Published
2007
Full Text
View/download PDF

14. Cardiovascular Outcomes With Atrial-Based Pacing Compared With Ventricular Pacing

Author

Healey, Jeffrey S., primary, Toff, William D., additional, Lamas, Gervasio A., additional, Andersen, Henning R., additional, Thorpe, Kevin E., additional, Ellenbogen, Kenneth A., additional, Lee, Kerry L., additional, Skene, Allan M., additional, Schron, Eleanor B., additional, Skehan, J. Douglas, additional, Goldman, Lee, additional, Roberts, Robin S., additional, Camm, A. John, additional, Yusuf, Salim, additional, and Connolly, Stuart J., additional

Published
2006
Full Text
View/download PDF

15. Relationship Between Uncontrolled Risk Factors and C-Reactive Protein Levels in Patients Receiving Standard or Intensive Statin Therapy for Acute Coronary Syndromes in the PROVE IT-TIMI 22 Trial

Author

Ray, Kausik K., primary, Cannon, Christopher P., additional, Cairns, Richard, additional, Morrow, David A., additional, Rifai, Nader, additional, Kirtane, Ajay J., additional, McCabe, Carolyn H., additional, Skene, Allan M., additional, Gibson, C. Michael, additional, Ridker, Paul M., additional, and Braunwald, Eugene, additional

Published
2005
Full Text
View/download PDF

18. Comparison of outcomes of patients with myocardial infarction when living alone versus those not living alone

Author

O’Shea, J.Conor, primary, Wilcox, Robert G, additional, Skene, Allan M, additional, Stebbins, Amanda L, additional, Granger, Christopher B, additional, Armstrong, Paul W, additional, Bode, Christoph, additional, Ardissino, Diego, additional, Emanuelsson, Hakan, additional, Aylward, Philip E, additional, White, Harvey D, additional, Sadowski, Zygmunt, additional, Topol, Eric J, additional, Califf, Robert M, additional, and Ohman, E.Magnus, additional

Published
2002
Full Text
View/download PDF

22. The Effect of Pioglitazone on Recurrent Myocardial Infarction in 2,445 Patients With Type 2 Diabetes and Previous Myocardial Infarction Results From the PROactive (PROactive 05) Study

Author

Erdmann, Erland, Dormandy, John A., Charbonnel, Bernard, Massi-Benedetti, Massimo, Moules, Ian K., and Skene, Allan M.

Abstract

ObjectivesThis analysis from the PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events) study assesses the effects of pioglitazone on mortality and macrovascular morbidity in patients with type 2 diabetes and a previous myocardial infarction (MI).BackgroundPeople with type 2 diabetes have an increased incidence of MI compared with the general population. Those with diabetes and MI have a worse prognosis than nondiabetic patients with cardiovascular disease.MethodsThe PROactive study was a prospective, multicenter, double-blind, placebo-controlled trial of 5,238 patients with type 2 diabetes and macrovascular disease. Patients were randomized to either pioglitazone or placebo in addition to their other glucose-lowering and cardiovascular medication. Treatment of diabetes, dyslipidemia, and hypertension was encouraged according to the International Diabetes Federation guidelines. Patients were followed for a mean of 2.85 years. The primary end point was the time to first occurrence of macrovascular events or death. Of the total cohort, the subgroup of patients who had a previous MI (n = 2,445 [46.7%]; n = 1,230 in the pioglitazone group and n = 1,215 in the placebo group) was evaluated using prespecified and post-hoc analyses.ResultsPioglitazone had a statistically significant beneficial effect on the prespecified end point of fatal and nonfatal MI (28% risk reduction [RR]; p = 0.045) and acute coronary syndrome (ACS) (37% RR; p = 0.035). There was a 19% RR in the cardiac composite end point of nonfatal MI (excluding silent MI), coronary revascularization, ACS, and cardiac death (p = 0.033). The difference in the primary end point defined in the main PROactive study did not reach significance in the MI population (12% RR; p = 0.135). The rates of heart failure requiring hospitalization were 7.5% (92 of 1,230) with pioglitazone and 5.2% (63 of 1,215) with placebo. Fatal heart failure rates were similar (1.4% [17 of the 92] with pioglitazone versus 0.9% [11 of the 63] with placebo).ConclusionsIn high-risk patients with type 2 diabetes and previous MI, pioglitazone significantly reduced the occurrence of fatal and nonfatal MI and ACS. (PROspective pioglitAzone Clinical Trial In macroVascular Events; http://www.clinicaltrials.gov/ct/show/NCT00174993?order = 1; ISRCTN NCT00174993).

Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results